IP Verse

Selective Sphingosine 1 Phosphate Receptor Modulators And Methods Of Chiral Synthesis - EP2498610

The patent EP2498610 was granted to Celgene II on Jun 19, 2024. The application was originally filed on Nov 15, 2010 under application number EP10830880A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2498610

CELGENE II
Application Number
EP10830880A
Filing Date
Nov 15, 2010
Status
Patent Maintained As Amended
May 17, 2024
Grant Date
Jun 19, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKDec 14, 2018ELKINGTON AND FIFEADMISSIBLE

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS5180741
DESCRIPTIONWO2004058149
DESCRIPTIONWO2009151529
INTERNATIONAL-SEARCH-REPORTUS2006161005
INTERNATIONAL-SEARCH-REPORTUS2007293545
INTERNATIONAL-SEARCH-REPORTUS2008009534
INTERNATIONAL-SEARCH-REPORTUS2008249093
INTERNATIONAL-SEARCH-REPORTUS6511975
INTERNATIONAL-SEARCH-REPORTWO2008076356
OPPOSITIONEP1912640
OPPOSITIONUS5180741
OPPOSITIONWO0222557
OPPOSITIONWO2004058149
OPPOSITIONWO2009080729
OPPOSITIONWO2009151529
SEARCHUS5180741
SEARCHWO2004058149
SEARCHWO2009151529

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Baumgart et al (2007), vol 369. pages 1641-1657-
OPPOSITION- Clinical trial number NCT02435992-
OPPOSITION- FDA approved label for Zeposia® (ozanimod)-
OPPOSITION- Feagan B. et al. Abstract P-012. The American Journal of Gastroenterology (2018). vol. 113. page S3-
OPPOSITION- Gonzalez-Cabrera et al. Mol. Pharmacol. 2008; 74(5) 1308-1318-
OPPOSITION- https://news.bms.com/news/details/2020/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-
OPPOSITION- https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-positive-topline results-pivotas-
OPPOSITION- https //www.crohnsstudies.com/home/new-clinical-trials/yellowstone-program/-
OPPOSITION- https //www ecco-ibd eu/publications/congress-abstracts/abstracts-2016/item/p372-a-multicentre-double-blind-placebo- controlled-parallel-group-proof-of-concept-study-to-evaluate-the-efficacy-safety-and-tolerability-of-the-s1p- receptor-modulator-krp203-in-subjects-with-moderately- active-refractory-ulcerative-colitis.html-
OPPOSITION- J. SONG et al., "A novel sphingosine 1-phosphate agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukine-10 gene -deficient mice", J. Pharmacology and Experimental Therapeutics, (20080000), vol. 324, no. 1, pages 276 - 283-
OPPOSITION- Juan Rivera; Richard L Proia; Ana Olivera, "The alliance of sphingosine 1-phosphate and its receptors in immunity", Nature Reviews Immunology, (20081000), vol. 8, pages 753 - 763-
OPPOSITION- Keller et al. The American journal of Pathology, Vol, 170, No.1, Jan 2007-
OPPOSITION- Pérez-Jeldres et al, Frontiers in Pharmacology. March 2019 Vol 10. Article 212-
OPPOSITION- Scott et al . British Journal of Pharmacology (2016) 173, 1778-1792-
OPPOSITION- Weisshof et al: Adv Ther(2018) 35: 1746-1762-
OPPOSITION- Zeposia (ozanimod) - An overview of Zeposia and why it is authorised in the EU-
OPPOSITION- Juan Rivera; Richard L Proia; Ana Olivera, "The alliance of sphingosine 1-phosphate and its receptors in immunity", Nature Reviews Immunology, (20081000), vol. 8, pages 753 - 763, XP055002039
OPPOSITION- J. SONG et al., "A novel sphingosine 1-phosphate agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukine-10 gene -deficient mice", J. Pharmacology and Experimental Therapeutics, (20080000), vol. 324, no. 1, pages 276 - 283, XP002566504

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents